Chakilia Moody
Acute Care · Flowood, MSNPI 1861049447
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,315 of the $9,607 with a category attached, or 76.1%. 28 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 35.0% of the total. Reporting peaked in 2024 at $3,505 and has fallen 95.9% since, to $144 in 2025. Among acute care clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $29.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- GSK$972
- Jazz Pharmaceuticals Inc.$827
- AstraZeneca$738
- Sanofi$732
- Boehringer Ingelheim$636
- plus $2K from 22 others
What the payments were for
- Travel & lodging$2,23223%
- Food & beverage$7,31576%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 32 | $3,367 |
| GSK | 80 | $972 |
| Jazz Pharmaceuticals Inc. | 33 | $827 |
| AstraZeneca | 15 | $738 |
| Sanofi | 24 | $732 |
| Boehringer Ingelheim | 32 | $636 |
| Mallinckrodt Hospital Products Inc. | 20 | $467 |
| Actelion Pharmaceuticals US, Inc. | 20 | $439 |
| Regeneron Healthcare Solutions, Inc. | 16 | $389 |
| Insmed, Inc. | 4 | $161 |
| Mylan Specialty L.p. | 7 | $149 |
| United Therapeutics Corporation | 5 | $106 |
| Axsome Therapeutics, Inc. | 3 | $91 |
| Baxter Healthcare | 5 | $91 |
| Bayer | 3 | $65 |
| Novo Nordisk | 3 | $56 |
| Harmony Biosciences LLC | 3 | $50 |
| ANI Pharmaceuticals, Inc. | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Amgen | 2 | $31 |
| 3b Medical, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $15 |
| Mayne Pharma Commercial LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,607 in reported general payments places this provider in the 95th percentile of 223 acute care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $122,816 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $31,581 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $25,183 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $17,133 |
| EliquisApixaban | 24 | $15,299 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $14,680 |
| Spiriva RespimatTiotropium Bromide | 23 | $11,640 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 19 | $7,660 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,020 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $5,764 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 151 | $4,760 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $3,684 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $1,530 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,277 |
| Montelukast Sodium | 87 | $786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $972 | $165,132229 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $738 | $53,921113 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $636 | $17,66036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 acute care providers in Mississippi.
Other acute care in Flowood
- Christopher BellTupelo$348K
- Kathleen ArnoldOcean Springs$217K
- Gavin GistOxford$42K
- Jamie DamicoOcean Springs$17K
- Dylan BoydHattiesburg$15K
- Melinda ClarkStarkville$14K
- Michelle TaylorGulfport$13K
- Aaron KatzenmeyerMadison$12K
- Megan WilliamsTupelo$11K
- Kimberly GonzalesHattiesburg$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.